Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Envoy Medical (COCH) Shares Outstanding (Weighted Average) (2022 - 2025)

Envoy Medical's Shares Outstanding (Weighted Average) history spans 4 years, with the latest figure at $23.3 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $23.3 million for Q4 2025, up 23.78% from a year ago — trailing twelve months through Dec 2025 was $23.3 million (up 23.78% YoY), and the annual figure for FY2025 was $23.3 million, up 23.78%.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $23.3 million at Envoy Medical, up from $21.5 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $42.5 million in Q2 2022 to a low of $10.1 million in Q2 2023.
  • The 4-year median for Shares Outstanding (Weighted Average) is $18.6 million (2024), against an average of $18.7 million.
  • Peak annual rise in Shares Outstanding (Weighted Average) hit 200.16% in 2023, while the deepest fall reached 76.18% in 2023.
  • Year by year, Shares Outstanding (Weighted Average) stood at $10.1 million in 2022, then increased by 21.46% to $12.3 million in 2023, then soared by 52.83% to $18.8 million in 2024, then grew by 23.78% to $23.3 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $23.3 million, $21.5 million, and $21.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.